Broad modulation of neuropathic pain states by a selective estrogen receptor beta agonist

Eur J Pharmacol. 2008 Aug 20;590(1-3):423-9. doi: 10.1016/j.ejphar.2008.05.015. Epub 2008 May 23.

Abstract

The effects of estrogens on pain perception remain controversial. In animal models, both beneficial and detrimental effects of non-selective estrogens have been reported. ERb-131 a non-steroidal estrogen receptor beta ligand was evaluated in several pain animal models involving nerve injury or sensitization. Using functional and binding assays, ERb-131 was characterized as a potent and selective estrogen receptor beta agonist. In vivo, ERb-131 was devoid of estrogen receptor alpha activity as assessed in a rat uterotrophic assay. ERb-131 alleviated tactile hyperalgesia induced by capsaicin, and reversed tactile allodynia caused by spinal nerve ligation and various chemical insults. Moreover, ERb-131 did not influence the pain threshold of normal healthy animals. Thus, estrogen receptor beta agonism is a critical effector in attenuating a broad range of anti-nociceptive states.

MeSH terms

  • Animals
  • Cells, Cultured
  • Dose-Response Relationship, Drug
  • Estradiol / analogs & derivatives
  • Estradiol / pharmacology
  • Estrogen Receptor beta / agonists*
  • Female
  • Fulvestrant
  • Humans
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Pain / drug therapy*
  • Pain Threshold / drug effects
  • Peripheral Nervous System Diseases / drug therapy*
  • Rats
  • Rats, Sprague-Dawley
  • Uterus / drug effects

Substances

  • Estrogen Receptor beta
  • Fulvestrant
  • Estradiol